Parkinson's disease (PD) usually occurs due to the degeneration of dopaminergic neurons
in the substantia nigra (SN). Management of PD is restricted to symptomatic improvement …

Historically the chemokine receptor CXCR4 and its canonical ligand CXCL12 are
associated with the bone marrow niche and hematopoiesis. However, CXCL12 exhibits …

Vildagliptin (Vilda), a dipeptidyl peptidase-4 (DPP-4) inhibitor, has been highlighted as a
promising therapeutic agent for neurodegenerative diseases as Alzheimer's and Parkinson's …

Alzheimer's disease (AD) and Type 2 diabetes mellitus (T2DM) are two of the most common
age-related diseases. There is accumulating evidence of an overlap in the …

Bovine casein is one of the most known precursors of bioactive peptides among food
proteins. Thus far, in silico investigations addressing casein have taken no account of the …

Dipeptidyl peptidase-4 (DPP-4) inhibitors are reported to exhibit promising effects on several
pathological processes associated with Parkinson's disease (PD). To explore its …

Abstract Background Dipeptidyl peptidase-IV (DPP-IV) inhibitors, the enhancers of incretin
are used for the treatment of diabetes. The non-glycaemic actions of these drugs (under …

Dipeptidyl peptidase 4 is a serine protease that cleaves X-proline or X-alanine in the
penultimate position. Natural substrates of the enzyme are glucagon-like peptide-1 …

Background Patients with type 2 diabetes mellitus (T2DM) are commonly at high risk for
developing cognitive dysfunction. Antidiabetic agents might be repurposed for targeting …

The complications of Alzheimer's disease (AD) have made the development of its treatment
a challenging task. Several studies have indicated the disruption of insulin receptor …